- Overview
- Bayer Group
- Stock
- Debt
- Reports
- Annual Stockholders’ Meeting 2019
- Events
- Inside Information
- News
- Investor News
- Press
- Archive
- Overview
- Investor News 2018
- Investor News 2017
- Investor News 2016
- Investor News 2015
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
- Handouts
- Downloads
- Service
Data on BAY 43-9006 at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
June 5 - 8, 2004, New Orleans
Background Information | |
---|---|
BAY 43-9006 Fact Sheet | Download PDF collect (184 KB) |
BAY 43-9006 Clinical Trial Overview | Download PDF collect (59 KB) |
Background Information on Renal Cell Cancer | Download PDF collect (148 KB) |
Background Information on Melanoma | Download PDF collect (27 KB) |
List of BAY 43-9006 Presentations at ASCO 2004 | Download PDF collect (168 KB) |
Glossary of Terms | Download PDF collect (133 KB) |
Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial: Abstract No: 4501
Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma: Abstract No: 7507
A randomized phase I clinical and biologic study of two schedules of BAY 43-9006 in patients with myelodysplastic syndrome or acute myeloid leukemia: A National Cancer Institute of Cancer Clinical Trials Group Study: Abstract No: 6611
A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer: Abstract No: 3059
Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors: Abstract No: 3049
Novel methodology of response assessment in hepatocellular carcinoma – Assessing response by change in tumor enhancement in distinction from conventional means: Abstract No: 3107
Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors: Abstract No: 3056
Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension: Abstract No: 2035
BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience: Abstract No: 7506
ASCO Homepage: www.asco.org
Clinical trials information: www.clinicaltrials.gov
American Cancer Society: www.cancer.org
Information on renal cell cancer: www.kidneycancerassociation.org
Information on melanoma: www.melanomainternational.org